ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,359.41
0.56%
Dow Jones
44,764.62
-0.04%
Gold vs US Dollar
2,644.29
0.07%
Brent Oil
73.56
2.32%
Bitcoin
95,747.71
-0.12%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Amarin Corp PLC (AMRN)

  7. Amarin Corp PLC (AMRN) News

Amarin (AMRN)

Amarin Corp PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMRN
DateTimeSourceHeadlineSymbolCompany
22/11/202421:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
11/11/202413:00GlobeNewswire Inc.Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) AnnualNASDAQ:AMRNAmarin Corp PLC
31/10/202420:42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
30/10/202420:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRNAmarin Corp PLC
30/10/202420:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
30/10/202420:05GlobeNewswire Inc.Amarin Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
01/10/202412:00GlobeNewswire Inc.Amarin Announces Two Upcoming Investor EventsNASDAQ:AMRNAmarin Corp PLC
09/09/202411:30GlobeNewswire Inc.Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual EuropeNASDAQ:AMRNAmarin Corp PLC
22/08/202412:30GlobeNewswire Inc.Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressNASDAQ:AMRNAmarin Corp PLC
05/08/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
01/08/202420:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
01/08/202420:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
31/07/202411:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
31/07/202411:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRNAmarin Corp PLC
31/07/202411:00GlobeNewswire Inc.Amarin Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
29/07/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
17/07/202420:15GlobeNewswire Inc.Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in PortugalNASDAQ:AMRNAmarin Corp PLC
17/07/202412:00GlobeNewswire Inc.Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024NASDAQ:AMRNAmarin Corp PLC
08/07/202411:30GlobeNewswire Inc.Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)NASDAQ:AMRNAmarin Corp PLC
04/06/202411:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
04/06/202411:30GlobeNewswire Inc.Amarin Board of Directors Announces CEO TransitionNASDAQ:AMRNAmarin Corp PLC
28/05/202412:15GlobeNewswire Inc. Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.NASDAQ:AMRNAmarin Corp PLC
06/05/202412:00GlobeNewswire Inc.Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:AMRNAmarin Corp PLC
01/05/202411:00GlobeNewswire Inc. Amarin Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:AMRNAmarin Corp PLC
24/04/202418:00GlobeNewswire Inc.Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventNASDAQ:AMRNAmarin Corp PLC
22/04/202412:00GlobeNewswire Inc.Amarin Announces Results of Annual General Meeting of ShareholdersNASDAQ:AMRNAmarin Corp PLC
15/04/202412:00GlobeNewswire Inc.Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024NASDAQ:AMRNAmarin Corp PLC
08/04/202412:00GlobeNewswire Inc.Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24NASDAQ:AMRNAmarin Corp PLC
08/04/202410:30PR Newswire (Canada)New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNASDAQ:AMRNAmarin Corp PLC
06/04/202419:30GlobeNewswire Inc.New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNASDAQ:AMRNAmarin Corp PLC
 Showing the most relevant articles for your search:NASDAQ:AMRN

Your Recent History

LSE
POS
Plexus
LSE
KEFI
Kefi Gold And Copper
LSE
DEC
Diversified Energy
LSE
OTB
On The Beach
LSE
BLU
Blue Star Capital
LSE
SYME
Supply@me Capital
LSE
GGP
Greatland Gold
LSE
PANR
Pantheon Resources
LSE
OPTI
Optibiotix Health
LSE
ORCP
Oracle Power
LSE
SCE
Surface Transforms
LSE
AAZ
Anglo Asian Mining
LSE
GPM
Golden Prospect Precious...
LSE
ITV
Itv
LSE
EEE
Empire Metals
LSE
UPS
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved